Higher dose corticosteroids for COVID-19

1

2 Higher dose corticosteroids in hospitalised COVID-19 3 patients with hypoxia but not requiring ventilatory 4 support (RECOVERY): a randomised, controlled, 5 open-label, platform trial 6 7 Running title: Higher dose corticosteroids for COVID-19 8 9 **RECOVERY Collaborative Group*** 10 11 12 *The Writing Committee and Trial Steering Committee are listed at the end of this 13 14 manuscript and a complete list of collaborators in the Randomised Evaluation of 15 COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix. 16 17 Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central 18 Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 19 7LF, United Kingdom. 20 Email: recoverytrial@ndph.ox.ac.uk 21 22 23

Higher dose corticosteroids for COVID-19

SUMMARY

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Background: Low-dose corticosteroids have been shown to reduce mortality for hypoxic COVID-19 patients requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation or extra-corporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group. Methods: This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting adult patients with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturation <92% on room air) were randomly allocated (1:1) to either usual care with higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once daily for 5 days or until discharge if sooner) or usual standard of care alone (which includes dexamethasone 6 mg once daily for 10 days or until discharge if sooner). The primary outcome was 28-day mortality. On 11 May 2022, the independent Data Monitoring Committee recommended stopping recruitment of patients receiving no oxygen or simple oxygen only to this comparison due to safety concerns. We report the results for these participants only. Recruitment of patients receiving ventilatory support continues. The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936). Findings: Between 25 May 2021 and 12 May 2022, 1272 COVID-19 patients with hypoxia and receiving no oxygen (1%) or simple oxygen only (99%) were randomly allocated to receive usual care plus higher dose corticosteroids versus usual care alone

Higher dose corticosteroids for COVID-19

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

(of whom 87% received low dose corticosteroids during the follow-up period). Of those randomised, 745 (59%) were in Asia, 512 (40%) in the UK and 15 (1%) in Africa, 248 (19%) had diabetes mellitus. Overall, 121 (18%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of 613 patients allocated to usual care died within 28 days (rate ratio [RR] 1.56; 95% CI 1.18-2.06; p=0.0020). There was also an excess of pneumonia reported to be due to non-COVID infection (10% vs. 6%; absolute difference 3.7%; 95% CI 0.7-6.6) and an increase in hyperglycaemia requiring increased insulin dose (22% vs. 14%; absolute difference 7.4%; 95% CI 3.2-11.5). **Interpretation:** In patients hospitalised for COVID-19 with clinical hypoxia but requiring either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared to usual care, which included low dose corticosteroids. The RECOVERY trial continues to assess the effects of higher dose corticosteroids in patients hospitalised with COVID-19 who require non-invasive ventilation, invasive mechanical ventilation or extra-corporeal membrane oxygenation. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health and Care Research (Grant ref: MC PC 19056), and Wellcome Trust (Grant Ref: 222406/Z/20/Z). **Keywords:** COVID-19, corticosteroid, dexamethasone, mortality, clinical trial.

Higher dose corticosteroids for COVID-19

INTRODUCTION

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

The RECOVERY trial has previously shown that the use of corticosteroids (using dexamethasone 6 mg once daily for ten days or until discharge if sooner) reduces the risk of death in patients admitted to hospital with COVID-19 and hypoxia. Subsequent findings that additional immunosuppression with an interleukin-6 (IL-6) receptor blocker and/or a Janus kinase (JAK) inhibitor further reduces the risk of death in these patients raises the question whether simply increasing the dose of corticosteroid rather than adding other immunomodulators could confer additional benefits at substantially lower cost.^{2,3} Initially, the dose of dexamethasone chosen for the RECOVERY trial was 6 milligrams once daily on the basis that there is considerable experience of using similar doses of corticosteroids safely for exacerbations of asthma and COPD. 4,5 However, the optimal corticosteroid dose in COVID-19 treatment has not been determined. Higher doses of corticosteroids have been used in non-COVID acute respiratory distress syndrome (ARDS) and in other COVID-19 clinical trials with reported clinical benefit, but these trials have been restricted to severe or critically ill patients and have not directly compared higher doses with the lower dose used in RECOVERY. 6-11 A WHO metaanalysis of randomised controlled trials in critically ill COVID-19 indicated similar mortality benefit with lower and higher-dose corticosteroids, but estimates were imprecise.9 In April 2021, the United Kingdom COVID-19 Therapeutics Advisory Panel recommended that the RECOVERY trial study higher dose of corticosteroids. 12 The

Higher dose corticosteroids for COVID-19

RECOVERY trial therefore established a randomised evaluation of the effects of higher-dose corticosteroids versus usual care for adult patients who had been admitted to hospital with COVID-19 and had clinical evidence of hypoxia. Usual care for hypoxic COVID-19 patients includes low dose corticosteroids. On 11 May 2022, the independent Data Monitoring Committee recommended that this comparison be halted for those patients receiving no oxygen or simple oxygen only on the grounds of safety. Here we report the results for these patients. Recruitment to this comparison continues as planned for patients receiving non-invasive ventilation or invasive mechanical ventilation.

METHODS

Study design and participants

The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-initiated, individually randomised, controlled, open-label, platform trial to evaluate the effects of potential treatments in patients hospitalised with COVID-19. Details of the trial design and results for other possible treatments (dexamethasone, hydroxychloroquine, lopinavir-ritonavir, azithromycin, tocilizumab, convalescent plasma, colchicine, aspirin, casirivimab plus imdevimab, and baricitinib) have been published previously. ^{1-3,13-19} The trial is underway at hospital organisations in the United Kingdom, supported by the National Institute for Health Research Clinical Research Network, as well as in South and Southeast Asia and Africa. Of these, 81 hospitals in the UK, 5 in Nepal, 2 in Indonesia, 2 in Vietnam, 2 in South Africa, and 1 in Ghana enrolled participants in the

Higher dose corticosteroids for COVID-19

evaluation of higher dose corticosteroids (appendix pp 2-31). The trial is coordinated by the Nuffield Department of Population Health at the University of Oxford (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles of the International Conference on Harmonisation—Good Clinical Practice guidelines. The protocol is approved by all relevant regulatory authorities and ethics committees in each participating country (appendix pp 32) The protocol and statistical analysis plan are available in the appendix (pp 71-152) with additional information available on the study website www.recoverytrial.net.

Patients aged at least 18 years admitted to hospital were eligible for the study if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection, clinical evidence of hypoxia (i.e. receiving oxygen with or without other forms of respiratory support, or with oxygen saturations <92% on room air) and no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Patients were ineligible for the comparison of higher dose corticosteroid vs. usual care if there was a known contra-indication to short-term use of corticosteroids, suspected or confirmed influenza, or current use of nirmatrelvir/ritonavir, ritonavir or other potent CYP3A inhibitors. Endemic infections were screened for as required by local practice. Other immunomodulatory therapies were not contra-indicated but investigators were advised to consider the total burden of such therapy (e.g. combining an IL-6 receptor antagonist with higher dose corticosteroid). Written informed consent was obtained from all patients, or a legal representative if patients were too unwell or unable to provide consent.

Randomisation and masking

Higher dose corticosteroids for COVID-19

Baseline data were collected using a web-based case report form that included demographics, level of respiratory support, major comorbidities, suitability of the study treatment for a particular patient, SARS-CoV-2 vaccination status, and treatment availability at the study site (appendix pp 44-47). Eligible and consenting patients were assigned in a 1:1 ratio to either usual standard of care plus higher dose corticosteroids or usual standard of care alone (which includes low dose corticosteroids, usually dexamethasone 6 mg once daily for 10 days or until discharge if sooner), using web-based simple (unstratified) randomisation with allocation concealed until after randomisation (appendix pp 42-44).^{20,21} Patients allocated to higher dose corticosteroid were to receive dexamethasone 20 mg daily for 5 days followed by dexamethasone 10 mg for 5 days (or until discharge if sooner). Alternative corticosteroid regimens for pregnant women are described in the protocol (appendix p 78). As a platform trial, and in a factorial design, patients could be simultaneously randomised to other treatment groups: i) empagliflozin versus usual care, ii) sotrovimab versus usual care, and iii) molnupiravir versus usual care. Further details of when these factorial randomisations were open are provided in the supplementary appendix (p 42-44). Participants and local study staff were not masked to the allocated treatment. The Trial Steering Committee, investigators, and all other individuals involved in the trial are masked to outcome data while recruitment and 28-day follow-up are ongoing.

Procedures

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

Higher dose corticosteroids for COVID-19

An online follow-up form was completed by site staff when patients were discharged, had died, or at 28 days after randomisation, whichever occurred first (appendix pp 48-56). Information was recorded on adherence to allocated trial treatment, receipt of other COVID-19 treatments, duration of admission, receipt of respiratory or renal support, new cardiac arrhythmia, thrombosis, clinically significant bleeding, non-COVID infection, metabolic complications (collected from 28 July 2021 onwards), and vital status (including cause of death). In addition, in the UK, routinely collected healthcare and registry data were obtained, including information on vital status at day 28 (with date and cause of death); discharge from hospital; and receipt of respiratory support or renal replacement therapy. For sites outside the UK a further case report form (appendix p 58) collected vital status at day 28 (if not already reported on follow-up form).

Outcomes

Outcomes were assessed at 28 days after randomisation, with further analyses specified at 6 months. The primary outcome was 28-day all-cause mortality. Secondary outcomes were time to discharge from hospital, and, among patients not on invasive mechanical ventilation at randomisation, the composite outcome of invasive mechanical ventilation (including extra-corporeal membrane oxygenation) or death. Prespecified subsidiary clinical outcomes were use of invasive or non-invasive ventilation among patients not on any ventilation at randomisation, and use of renal dialysis or haemofiltration among patients not receiving such treatment at randomisation. Prespecified safety outcomes were cause-specific mortality, major cardiac arrhythmia, thrombotic and major bleeding events, other infections and metabolic complications. Information on suspected serious adverse reactions was collected in an expedited

Higher dose corticosteroids for COVID-19

fashion to comply with regulatory requirements. Details of the methods used to ascertain and derive outcomes are provided in the appendix (pp.153-176).

Sample size and role of the independent Data Monitoring Committee

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

As stated in the protocol, appropriate sample sizes could not be estimated when the trial was being planned. However, the intention for this comparison was to continue recruitment until sufficient primary outcomes had accrued to have 90% power to detect a proportional risk reduction of 20% at 2P=0.01. The independent Data Monitoring Committee reviewed unblinded analyses of the study data and any other information considered relevant to the trial at intervals of around 2-3 months (depending on speed of enrolment) and was charged with determining if, in their view, the randomised comparisons in the study provided evidence on mortality that was strong enough (with a range of uncertainty around the results that was narrow enough) to affect national and global treatment strategies (appendix p 59). On 11 May 2022, the Data Monitoring Committee recommended stopping recruitment to the higher dose corticosteroid comparison for patients who require no oxygen or simple oxygen only at randomisation due to safety concerns (appendix p 60). The Data Monitoring Committee encouraged continuing recruitment of all those patients who, at randomisation, require either non-invasive ventilation, invasive mechanical ventilation or ECMO. On 13 May 2022, recruitment of patients on oxygen or simple oxygen only to this

comparison was stopped, investigators were notified and advised not to administer

Higher dose corticosteroids for COVID-19

further higher dose corticosteroids to this group as part of the trial. Follow-up of all patients continued as planned. The regulatory authorities and ethics committees in each participating country were notified. Trial procedures were changed as an urgent safety measure and the protocol was subsequently modified and approved accordingly. Recruitment and follow-up of patients receiving non-invasive ventilation or invasive mechanical ventilation remains open.

Statistical Analysis

All analyses were limited to the subgroup of patients on no or simple oxygen at randomization. For all outcomes, intention-to-treat analyses compared patients randomised to higher dose corticosteroids with patients randomised to usual care. For the primary outcome of 28-day mortality, the log-rank observed minus expected statistic and its variance were used to both test the null hypothesis of equal survival curves (i.e., the log-rank test) and to calculate the one-step estimate of the average mortality rate ratio. We constructed Kaplan-Meier survival curves to display cumulative mortality over the 28-day period. We used the same method to analyse time to hospital discharge with patients who died in hospital right-censored on day 29. Median time to discharge was derived from Kaplan-Meier estimates. For the composite secondary outcome of progression to invasive mechanical ventilation or death within 28 days, and the subsidiary clinical outcomes of receipt of ventilation and use of haemodialysis or haemofiltration, the precise dates were not available and so the risk ratio was estimated instead. Estimates of rate and risk ratios (both denoted RR) are shown with 95%

Higher dose corticosteroids for COVID-19

confidence intervals. For the primary outcome of 28-day mortality, a sensitivity analysis adjusted for age was done using Cox regression.

Since the analyses presented here relate only to the subset of participants who were on no oxygen or simple oxygen only at randomisation, any analyses of the primary outcome in further subgroups defined by different baseline characteristics must be considered exploratory in nature. With that caveat, we present analyses of the primary outcome by age, sex, ethnicity, days since symptom onset, and place of recruitment (UK, elsewhere) with tests of heterogeneity or trend, as appropriate. We have not presented analyses by subgroups for the secondary or other outcomes. Results for the pre-specified other clinical outcomes and safety outcomes are presented. The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK). Analyses were performed using SAS version 9.4 and R version 4.0.3. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Higher dose corticosteroids for COVID-19

RESULTS

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

Recruitment to the evaluation of higher dose corticosteroids commenced on 25 May 2021 outside the UK and 29 December 2021 in the UK (following closure of the baricitinib comparison) and ended worldwide for those on no oxygen or simple oxygen on 13 May 2022 following the Data Monitoring Committee recommendation.³ Of 1680 patients enrolled in this comparison during this period, 1272 patients on no oxygen or simple oxygen only are included in this evaluation. Of these, 659 were randomly allocated to higher dose corticosteroids and 613 patients were randomly allocated to usual care (Figure 1). The mean age of these participants was 61.1 years (SD 17.5) (webtable 1) with those randomly allocated to higher dose corticosteroids on average 1.9 years younger than those allocated usual care group (Table 1), 745 (59%) were in Asia, 512 (40%) in the UK, and 15 (1%) in Africa. 248 (19%) had a history of diabetes mellitus, and 1264 (99%) were receiving simple oxygen (webtable 1). The follow-up form was completed for 657 (99.7%) patients in the higher dose corticosteroid group and 608 (99.2%) patients in the usual care group. Among patients with a completed follow-up form, 91% allocated to higher dose corticosteroid were reported to have received higher dose corticosteroids compared with 1% allocated to usual care (figure 1, webtable 2). Among those with a completed follow-up form allocated usual care, 87% received low dose dexamethasone. Use of other treatments for COVID-19 was broadly similar among patients allocated higher dose corticosteroids and among those allocated usual care, with two-fifths receiving remdesivir and onetenth receiving an interleukin-6 antagonist during the follow-up period (webtable 2).

Higher dose corticosteroids for COVID-19

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

Primary and secondary outcome data are known for >99% of randomly assigned patients. Allocation to higher dose corticosteroids was associated with a significant increase in the primary outcome of 28-day mortality compared with usual care alone: 121 (18%) of 659 patients in the higher dose corticosteroid group died vs 75 (12%) of 613 patients in the usual care group (rate ratio 1.56; 95% CI 1.18-2.06; p=0.0020; table 2, figure 2). A similar proportional risk increase was seen in analyses restricted to participants with a positive SARS-CoV-2 PCR test (RR 1.63, 95% CI 1.22-2.17, p=0.0008) or adjusted for baseline age (RR 1.59, 95% CI 1.19-2.12, p=0.0017). In exploratory analyses, the proportional effect of higher dose corticosteroids on mortality was consistent across all 5 pre-specified subgroups (all interaction p-values ≥0.10; Figure 3), including by region of recruitment and by ethnicity. Discharge alive within 28 days was similar among those allocated to higher dose corticosteroids compared with usual care (80% vs. 82%; rate ratio 0.92, 95% CI 0.81 to 1.04; median 9 days [IQR 5 to 17] vs. 9 days [IQR 5 to 16]) (table 2; webfigure 1). Allocation to higher dose corticosteroids was associated with a higher risk of progressing to the composite secondary outcome of invasive mechanical ventilation or death (20% vs. 13%, risk ratio 1.50, 95% CI 1.16 to 1.94) (table 2; webfigure 2). There were no significant differences in use of ventilation or receipt of haemodialysis or haemofiltration (table 2). Three quarters of the deaths within 28 days were attributed to COVID-19 (webtable 3). Allocation to higher dose corticosteroids was associated with an increase in pneumonia reported as not due to COVID-19 (10% vs. 6%, absolute risk increase 3.7%, 95% CI 0.7 to 6.6; webtable 4), but there were no significant differences in the rates of other

Higher dose corticosteroids for COVID-19

presentations of non-coronavirus infection, new onset cardiac arrhythmia, thrombotic events, or clinically significant bleeding (webtable 4). Allocation to higher dose corticosteroids was associated with an increase in clinically significant hyperglycaemia (ketoacidosis, hyperglycaemic hyperosmolar state, or hyperglycaemia requiring new use of insulin) occurring in 22% vs. 14% participants (absolute risk increase 7.4%, 95% CI 3.2 to 11.5) (webtable 4). There were 37 reports (among 24 participants) of a serious adverse reaction believed to be related to treatment with higher dose corticosteroids (webtable 5), including 15 reports of a serious non-COVID infection, 9 with hyperglycaemia and 5 with gastro-intestinal bleeding.

DISCUSSION

In this large, randomised trial, allocation to higher dose corticosteroids significantly increased 28-day mortality for those patients with hypoxia requiring simple oxygen (or no oxygen). There was also an increase in the risk of pneumonia due to non-COVID-19 causes and in hyperglycaemic episodes requiring new use of insulin. This hazard appeared similar among patients from the UK and from Asia and Africa, where the prevalence of TB, HIV and other infections is greater. Within five days of receiving the DMC recommendation regarding the hazard associated with higher dose corticosteroids in this patient group, we had notified all investigators and relevant regulatory authorities and ethics committees, including the US Food and Drugs Administration, the European Medicines Agency, and the World Health Organization, and made the information publicly available via our public website.

Higher dose corticosteroids for COVID-19

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

Strengths of the RECOVERY trial are that it is randomised, has a large sample size, broad eligibility criteria and more than 99% of patients in this analysis have been followed up for the primary outcome. It was also conducted in areas with high (South and Southeast Asia, Africa) and low (UK) prevalence of HIV, TB, and other infections. The study has some limitations: this randomised trial is open label (i.e., participants and local hospital staff are aware of the assigned treatment), however, the outcome of death is unambiguous. Information on radiological, virological or physiological outcomes was not collected. Only about 10% of participants in this evaluation of high-dose corticosteroids received an interleukin-6 antagonist or baricitinib so we are unable to possible interactions between corticosteroid assess anv dose and immunomodulatory treatments. The enrolment of patients on no oxygen or simple oxygen was closed early on the basis of an interim analysis by the independent Data Monitoring Committee. Consequently, it is possible that the size of the hazards presented may be an over-estimate of the true effects of higher dose corticosteroids.²² Prior to the COVID-19 pandemic, the role of corticosteroids in acute lung injury was unclear.²³ This began to change when the RECOVERY trial showed a clear reduction in 28 days mortality with the use of 6mg dexamethasone once daily for up to 10 days in COVID-19 patients requiring oxygen therapy. The benefit of corticosteroids amongst critically ill COVID-19 patients was subsequently confirmed in other randomized controlled trials and in a meta-analysis. 9,24 A broader meta-analysis of the effects of corticosteroids in both COVID-related ARDS and non-COVID ARDS has reported that corticosteroids probably reduce mortality in patients with ARDS regardless of the aetiology.²⁵

Higher dose corticosteroids for COVID-19

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

Previous difficulties in determining the role of corticosteroids in acute lung injury may have arisen because the benefits and hazards of their use may vary by dose, comorbidities, and the severity of lung injury (which is reflected in the level of respiratory support required). 25,26 The initial dexamethasone result from RECOVERY showed a clear difference in effect of low-dose corticosteroids by disease severity (p value for trend <0.001), with the greatest benefit seen in the most severely ill. 28-day mortality was reduced by about one-third in those requiring invasive mechanical ventilation or ECMO, with a more modest reduction of one-fifth in those requiring simple oxygen or non-invasive ventilation, and no benefit observed in those not requiring oxygen.¹ The results we present in this paper show that in hypoxic COVID-19 patients who require only simply oxygen therapy, a higher dose of corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once daily for 5 days or until discharge if sooner) is harmful compared to usual care (which included use of lower dose corticosteroids). However, it remains an open question whether increasing the dose of corticosteroids above 6mg dexamethasone per day is helpful for COVID-19 patients requiring non-invasive or invasive mechanical ventilation - the RECOVERY trial continues to seek an answer for that question. In summary, this large, randomised trial demonstrates that, compared to standard dose corticosteroids, use of higher dose corticosteroids increases mortality for hypoxic patients with COVID-19 who are not receiving non-invasive or invasive mechanical ventilation.

Higher dose corticosteroids for COVID-19

Research in context

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

Evidence before this study We searched MEDLINE, Embase, MexRxiv and the WHO International Clinical Trials Registry Platform between Sept 1, 2019, and Nov 23, 2022 for randomised controlled trials comparing the effect of different doses of systemic corticosteroids in patients hospitalised with COVID-19 receiving no or simple oxygen at randomisation, using the search terms (Coronavirus infection OR SARS-CoV-2 OR SARS-CoV2 OR SARSCoV2 OR COVID OR COVID-19 OR COVID19 OR 2019-nCoV OR Coronavirus or Coronavirinae) AND (corticosteroid OR dexamethasone OR glucocorticoid OR steroid OR hydrocortisone OR methylprednisolone OR prednisolone OR betamethasone) and using validated filters to select for randomised controlled trials. No language restrictions were applied. We identified twelve relevant randomised trials with results available that assessed different doses of corticosteroids in hospitalised COVID-19 patients, at least some of whom were receiving simple oxygen therapy at randomisation: six assessed higher dose dexamethasone (12-24 mg per day) and six assessed methylprednisolone (60-1000 mg per day), all compared to lower dose dexamethasone (6-8 mg per day).²⁷⁻³⁸ Four of the trials included only a non-critically ill population and the remainder included a mixed illness severity population. ^{28,31,37,38} Eleven of the trials have been fully published of which five were considered to have low risk of bias for the 28-day mortality outcome and six having some concerns (including lack of information about randomisation process, lack of information about prespecified analyses, crossover between randomised groups and post-randomisation exclusion of patients in the

Higher dose corticosteroids for COVID-19

analysis population) (appendix p31). All but one of the trials have found no statistically significant difference in mortality between the treatment groups. The exception was a small trial comparing methylprednisolone (2mg/kg/day for 3 days then 1mg/kg/day for 3 days) with dexamethasone (8mg daily for 10 days) that included 140 patients and 18 deaths, that reported that methylprednisolone was associated with significantly improved mortality at 10 days.³⁸ There was no information in the trial report about the randomisation process or whether the trial was analysed as pre-specified, conferring some concerns over risk of bias.

Added value of this study:

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is the largest randomised trial of the effect of different doses of corticosteroids in patients hospitalised with COVID-19 and included patients from 3 continents. We found that among hypoxic patients on simple or no oxygen, randomisation to higher dose corticosteroids (dexamethasone 20 mg daily for 5 days followed by dexamethasone 10 mg for 5 days, or until discharge if sooner) vs. usual care (which included dexamethasone 6 mg once daily in 87% of participants) resulted in an increased risk of all-cause mortality, Overall, 121 (18%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of 613 patients allocated to usual care died within 28 days (rate ratio [RR] 1.56; 95% CI 1.18-2.06; p=0.0020). There was also an excess of pneumonia reported to be due to non-COVID infection (10% vs. 6%; absolute difference 3.7%; 95% CI 0.7-6.6) and an increase in hyperglycaemia requiring increased insulin dose (22% vs. 14%; absolute difference 7.4%; 95% CI 3.2-11.5).

Higher dose corticosteroids for COVID-19

Implications of all the available evidence:

Among hospitalised patients with COVID-19 who require oxygen or ventilatory support,
low-dose corticosteroids reduce the risk of death. However, among those requiring
simple oxygen only, higher doses of corticosteroids increase the risk of death compared
to low-dose corticosteroids. It remains unclear whether using a higher dose of
corticosteroids is beneficial among those requiring non-invasive or invasive ventilation —
the RECOVERY trial continues to study this question.

Higher dose corticosteroids for COVID-19

Contributors

407

420

431

408 This manuscript was initially drafted by the PWH and MJL, further developed by the 409 Writing Committee, and approved by all members of the Trial Steering Committee. PWH 410 and MJL vouch for the data and analyses, and for the fidelity of this report to the study 411 protocol and data analysis plan. PWH, BB, RLH, JA, JKB, MB, LCC, JD, SNF, TJ, EJ, 412 KJ, WSL, MM, AMo, AMu, KR, GT, RH, and MJL designed the trial and study protocol. 413 MM, LP, MC, G P-A, EK, MR, RKJ, NTP, US, DP, PNT, NN, ES, LM, RS, and the Data Linkage team at the RECOVERY Coordinating Centre, and the Health Records and 414 415 Local Clinical Centre staff listed in the appendix collected the data. NS and JRE had access to the study data and did the statistical analysis. All authors contributed to data 416 417 interpretation and critical review and revision of the manuscript. PWH and MJL had 418 access to the study data and had final responsibility for the decision to submit for 419 publication.

Writing Committee (on behalf of the RECOVERY Collaborative Group):

- Peter W Horby,* Jonathan R Emberson,* Buddha Basnyat,* Mark Campbell, Leon Peto,
- 422 Guilherme Pessoa-Amorim, Natalie Staplin, Raph L Hamers, John Amuasi, Jeremy Nel,
- 423 Evelyne Kestelyn, Manisha Rawal, Roshan Kumar Jha, Nguyen Thanh Phong, Uun
- 424 Samardi, Damodar Paudel, Pham Ngoc Thach, Nasronudin Nasronudin, Emma
- Stratton, Louise Mew, Rahul Sarkar, J Kenneth Baillie, Maya H Buch, Jeremy Day, Saul
- 426 N Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim,
- 427 Marion Mafham, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, †
- 428 Richard Haynes, * Martin J Landray. *
- 429 *PWH, JRE and BB made an equal contribution
- 430 ⁺ GT, RH and MJL made an equal contribution

Data Monitoring Committee

- 432 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo,
- 433 Mohammed Munavvar, Adilia Warris, Janet Wittes.

Higher dose corticosteroids for COVID-19

Declaration of interests

The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf).

Data sharing

The protocol, consent form, statistical analysis plan, definition & derivation of clinical characteristics & outcomes, training materials, regulatory documents, and other relevant study materials are available online at www.recoverytrial.net. As described in the protocol, the Trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. Deidentified participant data will be made available to bona fide researchers registered with an appropriate institution within 3 months of publication. However, the Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Steering Committee will have the right to review and comment on any draft manuscripts prior to publication. Data will be made available in line with the policy and procedures described at: https://www.ndph.ox.ac.uk/data-access.. Those wishing to request access should complete the form at

https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx

and e-mailed to: data.access@ndph.ox.ac.uk

Higher dose corticosteroids for COVID-19

Acknowledgements

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

Above all, we would like to thank the thousands of patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at participating hospital organisations. Supported in the UK by staff at the National Institute of Health and Care Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and Northern Ireland.

The RECOVERY trial is supported by grants to the University of Oxford from UK Research and Innovation (UKRI) and NIHR (MC_PC_19056), the Wellcome Trust (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator, and by core funding provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, □the □Bill and Melinda Gates Foundation, the □Foreign, Commonwealth and Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC UU 00002/14). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Tocilizumab, casirivimab and imdevimab, sotrovimab, and empagliflozin were provided through support from Roche, Regeneron, GSK, and Boehringer Ingelheim, respectively. Colchicine for use in Indonesia was provided by Combiphar. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Higher dose corticosteroids for COVID-19

489

Higher dose corticosteroids for COVID-19

References

490

- 491 1. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in
- 492 Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**(8): 693-704.
- 493 2. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital
- with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
- 495 Lancet 2021; **397**(10285): 1637-45.
- 496 3. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with
- 497 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and
- 498 updated meta-analysis. *Lancet* 2022; **400**(10349): 359-68.
- 499 4. National Institute for Health and Care Excellence. Chronic obstructive pulmonary
- disease in over 16s: diagnosis and management. 2019.
- 501 https://www.nice.org.uk/guidance/ng115/chapter/Recommendations#systemic-
- 502 corticosteroids (accessed 16 September 2022 2022).
- 503 5. National Institute for Health and Care Excellence. Oral corticosteroids for
- asthma. 2022. https://cks.nice.org.uk/topics/asthma/prescribing-information/oral-
- 505 <u>corticosteroids/</u> (accessed 16 September 2022).
- 506 6. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days
- 507 Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory
- 508 Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020;
- 509 **324**(13): 1307-16.
- 510 7. Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day
- Mortality or Respiratory Support Among Critically III Patients With COVID-19: A
- 512 Randomized Clinical Trial. *JAMA* 2020; **324**(13): 1298-306.
- 513 8. Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and
- 514 Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19
- 515 Corticosteroid Domain Randomized Clinical Trial. *JAMA* 2020; **324**(13): 1317-29.
- 516 9. WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne
- 517 JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids
- and Mortality Among Critically III Patients With COVID-19: A Meta-analysis. *JAMA* 2020;
- 519 **324**(13): 1330-41.
- 520 10. Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute
- respiratory distress syndrome: a multicentre, randomised controlled trial. *Lancet Respir*
- 522 *Med* 2020; **8**(3): 267-76.
- 523 11. Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse
- as a treatment for hospitalised severe COVID-19 patients: results from a randomised
- 525 controlled clinical trial. *Eur Respir J* 2020; **56**(6).

Higher dose corticosteroids for COVID-19

- 12. UK Research and Innovation. 13 April 2021 UK-CTAP: record of decisions. 2021.
- 527 https://www.ukri.org/publications/uk-covid-19-therapeutics-advisory-panel-records-of-
- 528 <u>decisions/13-april-2021-uk-ctap-record-of-decisions/</u> (accessed 16 September 2022).
- 13. RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of
- Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020;
- **383**(21): 2030-40.
- 14. RECOVERY Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-
- ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised,
- 534 controlled, open-label, platform trial. *Lancet* 2020; **396**(10259): 1345-52.
- 535 15. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital
- with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
- 537 Lancet 2021; **397**(10274): 605-12.
- 538 16. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to
- hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform
- 540 trial. *Lancet* 2021; **397**(10289): 2049-59.
- 541 17. RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with
- 542 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The*
- 543 Lancet Respiratory Medicine 2021.
- 18. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with
- 545 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*
- 546 2022; **399**(10320): 143-51.
- 547 19. RECOVERY Collaborative Group. Casirivimab and imdevimab in patients
- admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-
- 549 label, platform trial. *Lancet* 2022; **399**(10325): 665-76.
- 550 20. World Health Organization. Update to living WHO guideline on drugs for covid-
- 551 19. *BMJ* 2021; **372**: n860.
- 552 21. National Institute for Health and Care Excellence. COVID-19 rapid guideline:
- 553 Managing COVID-19., 2022.
- 554 22. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit
- and estimation of treatment effects: systematic review and meta-regression analysis.
- 556 *JAMA* 2010; **303**(12): 1180-7.
- 557 23. Mokra D, Mikolka P, Kosutova P, Mokry J. Corticosteroids in Acute Lung Injury:
- 558 The Dilemma Continues. *Int J Mol Sci* 2019; **20**(19).
- 559 24. Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope
- 560 During the Pandemic. *JAMA* 2020.

Higher dose corticosteroids for COVID-19

- 561 25. Chaudhuri D, Sasaki K, Karkar A, et al. Corticosteroids in COVID-19 and non-
- 562 COVID-19 ARDS: a systematic review and meta-analysis. *Intensive Care Med* 2021;
- 563 **47**(5): 521-37.
- 564 26. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W.
- 565 Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated
- Cochrane Systematic Review and Meta-analysis. *Crit Care Med* 2020; **48**(2): e98-e106.
- 567 27. Group CST, Munch MW, Myatra SN, et al. Effect of 12 mg vs 6 mg of
- Dexamethasone on the Number of Days Alive Without Life Support in Adults With
- 569 COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. *JAMA*
- 570 2021; **326**(18): 1807-17.
- 571 28. Toroghi N, Abbasian L, Nourian A, et al. Comparing efficacy and safety of
- different doses of dexamethasone in the treatment of COVID-19: a three-arm
- 573 randomized clinical trial. *Pharmacol Rep* 2022; **74**(1): 229-40.
- 574 29. Montalvan E, Carcamo B, Palacion D, et al. High-dose vs low-dose
- 575 dexamethasone in patients with COVID-19 in a tertiary hospital in western Honduras.
- 576 Chest 2021; **160**(4): A1117-A8.
- 577 30. Bouadma L, Mekontso-Dessap A, Burdet C, et al. High-Dose Dexamethasone
- and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19
- 579 Acute Hypoxemic Respiratory Failure: The COVIDICUS Randomized Clinical Trial.
- 580 JAMA Internal Medicine 2022.
- 581 31. Taboada M, Rodriguez N, Varela PM, et al. Effect of high versus low dose of
- dexamethasone on clinical worsening in patients hospitalised with moderate or severe
- 583 COVID-19 pneumonia: an open-label, randomised clinical trial. *Eur Respir J* 2022;
- 584 **60**(2).
- 585 32. Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or
- dexamethasone, which one is superior corticosteroid in the treatment of hospitalized
- 587 COVID-19 patients: a triple-blinded randomized controlled trial. *BMC Infect Dis* 2021;
- 588 **21**(1): 337.
- 589 33. Salvarani C, Massari M, Costantini M, et al. Intravenous methylprednisolone
- 590 pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind,
- randomised, placebo-controlled trial. *Eur Respir J* 2022.
- 592 34. Dastenae ZH, Bahadori A, Dehghani M, Asadi-Samani M, Izadi I, Shahraki HR.
- 593 Comparison of the effect of intravenous dexamethasone and methylprednisolone on the
- treatment of hospitalized patients with COVID-19: A randomized clinical trial. *Int J Infect*
- 595 *Dis* 2022; **122**: 659-64.
- 596 35. Wu H, Daouk S, Kebbe J, Chaudry F, Harper J, Brown B. Low-dose versus high-
- 597 dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A
- 598 randomized clinical trial. *PloS one* 2022; **17(10)**: e0275217.

Higher dose corticosteroids for COVID-19

- 599 36. Salton F, Confalonieri P, Centanni S, et al. Prolonged higher dose
- methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a
- randomised controlled trial (MEDEAS). *The European respiratory journal* 2022; **10**.
- 602 37. Corral-Gudino L, Cuascovich I, Martin-Gonzalez JI, et al. Effect of intravenous
- pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised
- adults with severe COVID-19 pneumonia: An open-label randomised trial. *European*
- 605 Journal of Clinical Investigation: e13881.

609

- 606 38. Gautam PB, Kumar A, Kannojia BL, Chaudhary R. A comparative study of the
- 607 efficacy and outcome of methylprednisolone and dexamethasone in moderate to severe
- 608 COVID-19 disease. Asian Journal of Medical Sciences 2021; 12(12): 17-22.

Table 1: Baseline characteristics by treatment allocation

	Treatmo	Treatment allocation		
	High dose (n=659)	Low dose (n=613)		
Age, years	60.2 (18.3)	62.1 (16.6)		
<70	426 (65%)	395 (64%)		
≥70 to <80	128 (19%)	122 (20%)		
≥80	105 (16%)	96 (16%)		
Sex	,	, ,		
Male	393 (60%)	376 (61%)		
Female	266 (40%)	236 (38%)		
Country	, ,	, ,		
Ghana	1 (<0.5%)	0 (0%)		
Indonesia	41 (6%)	31 (5%)		
Nepal	317 (48%)	288 (47%)		
South Africa	11 (2%)	3 (<0.5%)		
Vietnam	40 (6%)	28 (5%)		
United Kingdom	249 (38%)	263 (43%)		
Ethnicity	,	, ,		
White	220 (33%)	222 (36%)		
Black	6 (1%)	8 (1%)		
Asian	363 (55%)	325 (53%)		
Other	2 (<0.5%)	7 (1%)		
Unknown	68 (10%)	51 (8%)		
Number of days since symptom onset	7 (4-10)	7 (4-10)		
Number of days since admission to hospital	1 (0-2)	1 (1-3)		
Respiratory support received				
None	5 (1%)	3 (<0.5%)		
Simple oxygen	654 (99%)	610 (100%)		
Previous diseases				
Diabetes	129 (20%)	119 (19%)		
Heart disease	186 (28%)	165 (27%)		
Chronic lung disease	135 (20%)	134 (22%)		
Tuberculosis	5 (1%)	5 (1%)		
HIV	3 (<0.5%)	3 (<0.5%)		
Severe liver disease *	5 (1%)	7 (1%)		
Severe kidney impairment †	22 (3%)	18 (3%)		
Any of the above	338 (51%)	307 (50%)		
SARS-CoV-2 PCR test result				
Positive	623 (95%)	581 (95%)		
Negative	5 (1%)	4 (1%)		
Unknown	31 (5%)	28 (5%)		
Received a COVID-19 vaccine	358 (54%)	317 (52%)		
Use of other treatments				
Remdesivir	221 (34%)	206 (34%)		
Tocilizumab	57 (9%)	46 (8%)		
Plan to use tocilizumab within the next 24 hours	26 (4%)	26 (4%)		

Data are mean (SD), n (%), or median (IQR). 3 pregnant women were randomised. * Defined as requiring ongoing specialist care. † Defined as estimated glomerular filtration rate $<30 \text{ mL/min per } 1.73 \text{ m}^2$

Table 2: Effect of allocation to higher dose corticosteroid on key study outcomes

	Treat		
	High dose steroids (n=659)	Usual care (n=613)	RR (95% CI)
Primary outcome			
28-day mortality	121 (18.4%)	75 (12.2%)	1.56 (1.18-2.06)
Secondary and other key outcomes			
Median duration of hospitalization, days	9 (5 to 17)	9 (5 to 16)	
Discharged from hospital alive within 28 days	527 (80.0%)	505 (82.4%)	0.92 (0.81-1.04)
Invasive mechanical ventilation or death within 28 days	129 (19.6%)	80 (13.1%)	1.50 (1.16-1.94)
Use of ventilation	119 (18.1%)	84 (13.7%)	1.32 (1.02-1.70)
Non-invasive ventilation	108 (16.4%)	82 (13.4%)	1.23 (0.94-1.60)
Invasive mechanical ventilation	22 (3.3%)	14 (2.3%)	1.46 (0.75-2.83)
Renal replacement therapy (RRT) *	12/659 (1.8%)	8/613 (1.3%)	1.40 (0.57-3.39)

Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality and hospital discharge, and risk ratio for other outcomes. CI=confidence interval. * Analyses exclude those on haemodialysis or haemofiltration at randomisation.

Figures

Figure 1: Trial profile

ITT=intention to treat. Higher dose corticosteroid unavailable and higher dose corticosteroid considered unsuitable are not mutually exclusive. High risk patients are those that were receiving non-invasive ventilation, invasive mechanical ventilation or ECMO at randomisation. Low risk patients are those that were hypoxic but receiving no oxygen or simple oxygen only. * Number recruited overall during period that participants on no oxygen or simple oxygen only could be recruited into the higher dose corticosteroid comparison.

Figure 2: Effect of allocation to higher dose corticosteroids or usual care (lower dose corticosteroids) on 28-day mortality in patients receiving no oxygen or simple oxygen only

RR = rate ratio

Figure 3: Effect of allocation to higher dose corticosteroids or usual care (lower dose corticosteroids) on 28-day mortality in patients receiving no oxygen or simple oxygen only by other baseline characteristics.

Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% CIs. The days since onset subgroup excludes those with missing data, but these patients are included in the overall summary diamond. RR=rate ratio.

Figure 1: Trial profile
medRxiv preprint doi: https://doi.org/10.1101/2022.12.16.22283578; this version posted December 17, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.




Figure 2: Effect of allocation to high dose steroids vs usual care on 28-day morreal intermediation (special property) and a copyright holder for this preprint (mych was property). The copyright holder for this preprint (mych was property) and the preprint in perpetuity.




Figure 3: Effect of allocation to high dose steroids vs usual care on 28-day mortality in patients receiving no oxygen or simple oxygen only, by other baseline characteristics

High	n dose steroids	Usual care	О-Е	٧		RR (95% CI)
Age, years (χ_1^2 = 0.3; p=0.56)						
<70	48/426 (11%)	35/395 (9%)	5.4	20.6 —	 -	1.30 (0.84-2.00)
≥70 <80	34/128 (27%)	15/123 (12%)	10.0	12.1	\longrightarrow	2.29 (1.31–4.03)
≥80	39/105 (37%)	25/95 (26%)		15.7	-	1.53 (0.93–2.50)
Sex (χ_1^2 = 0.0; p=0.89)						
Men	79/393 (20%)	51/376 (14%)	14.0	32.2	- _	1.54 (1.09-2.18)
Women	42/266 (16%)	24/236 (10%)	7.8	16.4	-	1.61 (0.99–2.61)
Ethnicity (χ_1^2 = 0.3; p=0.60)						
White	56/227 (25%)	35/226 (15%)	11.6	22.5		1.68 (1.11-2.53)
Black, Asian and Minority Ethnic	56/371 (15%)	37/340 (11%)	8.3	23.1	 	1.43 (0.95–2.16)
Country ($\chi_1^2 = 0.4$; p=0.53)						
UK	61/249 (24%)	39/263 (15%)	13.8	24.7		1.75 (1.18-2.60)
Other countries	60/410 (15%)	36/350 (10%)	9.1	23.8	 	1.46 (0.98–2.19)
Days since symptom onset (x2	² = 2.7; p=0.10)					
≤7	74/384 (19%)	36/346 (10%)	17.8	27.3		1.92 (1.32-2.80)
>7	47/275 (17%)	39/267 (15%)	3.7	21.3 —	 	1.19 (0.78–1.82)
All participants	121/659 (18%)	75/613 (12%)	21.6	48.6		1.56 (1.18–2.06) p=0.002
					 	•
				0.75	1 1.5 2 3	
				igh dose oids bette	Usual care r better	